{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T22:07:55Z","timestamp":1794780475747,"version":"4.9.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA232382"],"award-info":[{"award-number":["U01CA232382"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA274507"],"award-info":[{"award-number":["U54CA274507"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Syst Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chemotherapy remains a commonly used and important treatment option for metastatic breast cancer. A majority of Estrogen Receptor-positive (ER\u2009+\u2009) metastatic breast cancer patients ultimately develop resistance to chemotherapy, resulting in disease progression. We hypothesized that an \u201cevolutionary double-bind\u201d, where adapting to one treatment inadvertently makes cancer cells more susceptible to another treatment, would improve the effectiveness and durability of response to chemotherapy. This approach exploits vulnerabilities in acquired resistance mechanisms. Evolutionary models can be used to identify alternative treatment strategies that capitalize on such vulnerabilities in refractory cancers, leading to improved outcomes. To develop and test these models, ER+ breast cancer cell lineages sensitive and resistant to chemotherapy were grown in spheroids with varied initial population frequencies to measure cross-sensitivity and efficacy of chemotherapy and add-on treatments, such as disulfiram. Different treatment schedules were evaluated to identify the most effective strategy for reducing the selection of resistant populations, thereby preventing their proliferation and dominance. We developed a game-theoretic mathematical model, parameterized from this in vitro experimental data, and used it to predict the existence of a double-bind, where selection for resistance to chemotherapy induces sensitivity to disulfiram. The model predicts a dose-dependent re-sensitization to chemotherapy for monotherapy disulfiram.<\/jats:p>","DOI":"10.1038\/s44320-026-00191-z","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:17:29Z","timestamp":1774545449000},"page":"1070-1096","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4450-0088","authenticated-orcid":false,"given":"Rena","family":"Emond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9579-4664","authenticated-orcid":false,"given":"Jeffrey","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5677-895X","authenticated-orcid":false,"given":"Vince K","family":"Grolmusz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7784-7785","authenticated-orcid":false,"given":"Patrick A","family":"Cosgrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aritro","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-4383","authenticated-orcid":false,"given":"Alexander R A","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4850-0453","authenticated-orcid":false,"given":"Andrea H","family":"Bild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"191_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coisb.2019.09.001","volume":"17","author":"FR Adler","year":"2019","unstructured":"Adler FR, Gordon DM (2019) Cancer ecology and evolution: positive interactions and system vulnerability. Curr Opin Syst Biol 17:1\u20137","journal-title":"Curr Opin Syst Biol"},{"key":"191_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25927-3","volume":"12","author":"LBS Aulin","year":"2021","unstructured":"Aulin LBS, Liakopoulos A, Graaf PH, van der, Rozen DE, Hasselt JGCvan (2021) Design principles of collateral sensitivity-based dosing strategies. Nat Commun 12:5691","journal-title":"Nat Commun"},{"key":"191_CR3","doi-asserted-by":"crossref","unstructured":"Basanta D, Gatenby RA, Anderson ARA (2012) Exploiting evolution to treat drug resistance: combination therapy and the double bind. Mol Pharm 9:914\u2013921","DOI":"10.1021\/mp200458e"},{"key":"191_CR4","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1021\/mp200458e","volume":"9","author":"D Basanta","year":"2012","unstructured":"Basanta D, Gatenby RA, Anderson AR (2012a) Exploiting evolution to treat drug resistance: combination therapy and the double bind. Mol Pharm 9:914\u2013921","journal-title":"Mol Pharm"},{"key":"191_CR5","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1021\/mp200458e","volume":"9","author":"D Basanta","year":"2012","unstructured":"Basanta D, Gatenby RA, Anderson ARA (2012b) Exploiting evolution to treat drug resistance: combination therapy and the double bind. Mol Pharm 9:914\u2013921","journal-title":"Mol Pharm"},{"key":"191_CR6","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.2147\/CMAR.S199912","volume":"11","author":"W Bu","year":"2019","unstructured":"Bu W, Wang Z, Meng L, Li X, Liu X, Chen Y, Xin Y, Li B, Sun H (2019) Disulfiram inhibits epithelial\u2013mesenchymal transition through TGF\u03b2\u2013ERK\u2013Snail pathway independently of Smad4 to decrease oral squamous cell carcinoma metastasis. Cancer Manag Res 11:3887\u20133898","journal-title":"Cancer Manag Res"},{"key":"191_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2174\/138161282005140214165212","volume":"20","author":"Y Choi","year":"2014","unstructured":"Choi Y, Yu A-M (2014) ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 20:793\u2013807","journal-title":"Curr Pharm Des"},{"key":"191_CR8","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/s41598-017-00791-8","volume":"7","author":"A Dhawan","year":"2017","unstructured":"Dhawan A, Nichol D, Kinose F, Abazeed ME, Marusyk A, Haura EB, Scott JG (2017) Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer. Sci Rep 7:1232","journal-title":"Sci Rep"},{"key":"191_CR9","doi-asserted-by":"publisher","first-page":"125102","DOI":"10.1088\/0957-4484\/25\/12\/125102","volume":"25","author":"X Duan","year":"2014","unstructured":"Duan X, Xiao J, Yin Q, Zhang Z, Yu H, Mao S, Li Y (2014) Multi-targeted inhibition of tumor growth and lung metastasis by redox-sensitive shell crosslinked micelles loading disulfiram. Nanotechnology 25:125102","journal-title":"Nanotechnology"},{"key":"191_CR10","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"(EBCTCG) EBCTCG","year":"2005","unstructured":"(EBCTCG) EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687\u20131717","journal-title":"Lancet"},{"key":"191_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39242-6","volume":"14","author":"R Emond","year":"2023","unstructured":"Emond R, Griffiths JI, Grolmusz VK, Nath A, Chen J, Medina EF, Sousa RS, Synold T, Adler FR, Bild AH (2023) Cell facilitation promotes growth and survival under drug pressure in breast cancer. Nat Commun 14:3851","journal-title":"Nat Commun"},{"key":"191_CR12","doi-asserted-by":"publisher","first-page":"eabm7212","DOI":"10.1126\/sciadv.abm7212","volume":"8","author":"N Farrokhian","year":"2022","unstructured":"Farrokhian N, Maltas J, Dinh M, Durmaz A, Ellsworth P, Hitomi M, McClure E, Marusyk A, Kaznatcheev A, Scott JG (2022) Measuring competitive exclusion in non\u2013small cell lung cancer. Sci Adv 8:eabm7212","journal-title":"Sci Adv"},{"key":"191_CR13","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.1038\/s41598-021-84406-3","volume":"11","author":"AR Freischel","year":"2021","unstructured":"Freischel AR, Damaghi M, Cunningham JJ, Ibrahim-Hashim A, Gillies RJ, Gatenby RA, Brown JS (2021a) Frequency-dependent interactions determine outcome of competition between two breast cancer cell lines. Sci Rep 11:4908","journal-title":"Sci Rep"},{"key":"191_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-84406-3","volume":"11","author":"AR Freischel","year":"2021","unstructured":"Freischel AR, Damaghi M, Cunningham JJ, Ibrahim-Hashim A, Gillies RJ, Gatenby RA, Brown JS (2021b) Frequency-dependent interactions determine outcome of competition between two breast cancer cell lines. Sci Rep 11:1\u201318","journal-title":"Sci Rep"},{"key":"191_CR15","doi-asserted-by":"publisher","first-page":"7499","DOI":"10.1158\/0008-5472.CAN-09-1354","volume":"69","author":"RA Gatenby","year":"2009","unstructured":"Gatenby RA, Brown J, Vincent T (2009a) Lessons from applied ecology: cancer control using an evolutionary double bind. Cancer Res 69:7499\u20137502","journal-title":"Cancer Res"},{"key":"191_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41571-020-0411-1","volume":"17","author":"RA Gatenby","year":"2020","unstructured":"Gatenby RA, Brown JS (2020) Integrating evolutionary dynamics into cancer therapy. Nat Rev Clin Oncol 17:675\u2013686","journal-title":"Nat Rev Clin Oncol"},{"key":"191_CR17","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","volume":"69","author":"RA Gatenby","year":"2009","unstructured":"Gatenby RA, Silva AS, Gillies RJ, Frieden BR (2009b) Adaptive therapy. Cancer Res 69:4894\u20134903","journal-title":"Cancer Res"},{"key":"191_CR18","doi-asserted-by":"publisher","first-page":"1406744","DOI":"10.3389\/fonc.2024.1406744","volume":"14","author":"L Gourmet","year":"2024","unstructured":"Gourmet L, Walker-Samuel S, Mallick P (2024) Examination of the role of mutualism in immune evasion. Front Oncol 14:1406744","journal-title":"Front Oncol"},{"key":"191_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01337-1","volume":"20","author":"VK Grolmusz","year":"2020","unstructured":"Grolmusz VK, Chen J, Emond R, Cosgrove PA, Pflieger L, Nath A, Moos PJ, Bild AH (2020) Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model. Cancer Cell Int 20:253","journal-title":"Cancer Cell Int"},{"key":"191_CR20","doi-asserted-by":"publisher","first-page":"40907","DOI":"10.18632\/oncotarget.5723","volume":"6","author":"D Han","year":"2015","unstructured":"Han D, Wu G, Chang C, Zhu F, Xiao Y, Li Q, Zhang T, Zhang L (2015) Disulfiram inhibits TGF-\u03b2-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK\/NF-\u03baB\/Snail pathway. Oncotarget 6:40907\u201340919","journal-title":"Oncotarget"},{"key":"191_CR21","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41590-020-0669-6","volume":"21","author":"JJ Hu","year":"2020","unstructured":"Hu JJ, Liu X, Xia S, Zhang Z, Zhang Y, Zhao J, Ruan J, Luo X, Lou X, Bai Y et al (2020) FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol 21:736\u2013745","journal-title":"Nat Immunol"},{"key":"191_CR22","doi-asserted-by":"crossref","unstructured":"Hwangbo H, Patterson S, Dai A, Plana D, Palmer AC (2023) Additivity predicts the efficacy of most approved combination therapies for advanced cancer. Nat Cancer 4:1693\u20131704","DOI":"10.1038\/s43018-023-00667-z"},{"key":"191_CR23","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.1158\/1078-0432.CCR-09-1035","volume":"15","author":"K Iljin","year":"2009","unstructured":"Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, Grafstr\u00f6m RC, Per\u00e4l\u00e4 M, Kallioniemi O (2009) High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res 15:6070\u20136078","journal-title":"Clin Cancer Res"},{"key":"191_CR24","doi-asserted-by":"publisher","first-page":"108800","DOI":"10.1016\/j.biopha.2019.108800","volume":"114","author":"X Ji","year":"2019","unstructured":"Ji X, Lu Y, Tian H, Meng X, Wei M, Cho WC (2019) Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother 114:108800","journal-title":"Biomed Pharmacother"},{"key":"191_CR25","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/s41418-023-01167-4","volume":"30","author":"DC Kanellis","year":"2023","unstructured":"Kanellis DC, Zisi A, Skrott Z, Lemmens B, Espinoza JA, Kosar M, Bj\u00f6rkman A, Li X, Arampatzis S, Bartkova J et al (2023) Actionable cancer vulnerability due to translational arrest, p53 aggregation and ribosome biogenesis stress evoked by the disulfiram metabolite CuET. Cell Death Differ 30:1666\u20131678","journal-title":"Cell Death Differ"},{"key":"191_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41559-018-0768-z","volume":"3","author":"A Kaznatcheev","year":"2019","unstructured":"Kaznatcheev A, Peacock J, Basanta D, Marusyk A, Scott JG (2019a) Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer. Nat Ecol Evol 3:450","journal-title":"Nat Ecol Evol"},{"key":"191_CR27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41559-018-0768-z","volume":"3","author":"A Kaznatcheev","year":"2019","unstructured":"Kaznatcheev A, Peacock J, Basanta D, Marusyk A, Scott JG (2019b) Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer. Nat Ecol Evol 3:450\u2013456","journal-title":"Nat Ecol Evol"},{"key":"191_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1158\/2159-8290.CD-22-0236","volume":"13","author":"K Kim","year":"2022","unstructured":"Kim K, Huang H, Parida PK, He L, Marquez-Palencia M, Reese TC, Kapur P, Brugarolas J, Brekken RA, Malladi S (2022) Cell competition shapes metastatic latency and relapse. Cancer Discov 13:85\u201397","journal-title":"Cancer Discov"},{"key":"191_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.canlet.2015.07.029","volume":"369","author":"Y Li","year":"2015","unstructured":"Li Y, Fu S-Y, Wang L-H, Wang F-Y, Wang N-N, Cao Q, Wang Y-T, Yang J-Y, Wu C-F (2015) Copper improves the anti-angiogenic activity of disulfiram through the EGFR\/Src\/VEGF pathway in gliomas. Cancer Lett 369:86\u201396","journal-title":"Cancer Lett"},{"key":"191_CR30","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1021\/mp049917l","volume":"1","author":"TW Loo","year":"2004","unstructured":"Loo TW, Bartlett MC, Clarke DM (2004) Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein. Mol Pharm 1:426\u2013433","journal-title":"Mol Pharm"},{"key":"191_CR31","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1093\/jnci\/92.11.898","volume":"92","author":"TW Loo","year":"2000","unstructured":"Loo TW, Clarke DM (2000) Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J Natl Cancer Inst 92:898\u2013902","journal-title":"J Natl Cancer Inst"},{"key":"191_CR32","doi-asserted-by":"publisher","first-page":"032408","DOI":"10.1103\/PhysRevE.103.032408","volume":"103","author":"Y Ma","year":"2021","unstructured":"Ma Y, Newton P (2021) Role of synergy and antagonism in designing multidrug adaptive chemotherapy schedules. Phys Rev E 103:032408","journal-title":"Phys Rev E"},{"key":"191_CR33","doi-asserted-by":"publisher","first-page":"955","DOI":"10.4161\/cbt.10.10.13879","volume":"10","author":"GK Malhotra","year":"2010","unstructured":"Malhotra GK, Zhao X, Band H, Band V (2010) Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther 10:955\u2013960","journal-title":"Cancer Biol Ther"},{"key":"191_CR34","doi-asserted-by":"publisher","first-page":"1175503","DOI":"10.3389\/fimmu.2023.1175503","volume":"14","author":"N Manduca","year":"2023","unstructured":"Manduca N, Maccafeo E, Maria RD, Sistigu A, Musella M (2023) 3D cancer models: one step closer to in vitro human studies. Front Immunol 14:1175503","journal-title":"Front Immunol"},{"key":"191_CR35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/ijc.1565","volume":"97","author":"M Marikovsky","year":"2002","unstructured":"Marikovsky M, Nevo N, Vadai E, Harris-Cerruti C (2002) Cu\/Zn superoxide dismutase plays a role in angiogenesis. Int J Cancer 97:34\u201341","journal-title":"Int J Cancer"},{"key":"191_CR36","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.neo.2021.08.001","volume":"23","author":"F Marongiu","year":"2021","unstructured":"Marongiu F, Cheri S, Laconi E (2021) Cell competition, cooperation, and cancer. Neoplasia 23:1029\u20131036","journal-title":"Neoplasia"},{"key":"191_CR37","doi-asserted-by":"publisher","first-page":"108575","DOI":"10.1016\/j.mbs.2021.108575","volume":"336","author":"MR Messan","year":"2021","unstructured":"Messan MR, Damaghi M, Freischel A, Miao Y, Brown J, Gillies R, Wallace D (2021) Predicting the results of competition between two breast cancer lines grown in 3-D spheroid culture. Math Biosci 336:108575","journal-title":"Math Biosci"},{"key":"191_CR38","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.tips.2020.01.011","volume":"41","author":"CT Meyer","year":"2020","unstructured":"Meyer CT, Wooten DJ, Lopez CF, Quaranta V (2020) Charting the fragmented landscape of drug synergy. Trends Pharmacol Sci 41:266\u2013280","journal-title":"Trends Pharmacol Sci"},{"key":"191_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cels.2019.01.003","volume":"8","author":"CT Meyer","year":"2019","unstructured":"Meyer CT, Wooten DJ, Paudel BB, Bauer J, Hardeman KN, Westover D, Lovly CM, Harris LA, Tyson DR, Quaranta V (2019a) Quantifying drug combination synergy along potency and efficacy axes. Cell Syst 8:97\u2013108.e16","journal-title":"Cell Syst"},{"key":"191_CR40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cels.2019.01.003","volume":"8","author":"CT Meyer","year":"2019","unstructured":"Meyer CT, Wooten DJ, Paudel BB, Bauer J, Hardeman KN, Westover D, Lovly CM, Harris LA, Tyson DR, Quaranta V (2019b) Quantifying drug combination synergy along potency and efficacy axes. Cell Syst 8:97\u2013108.e16","journal-title":"Cell Syst"},{"key":"191_CR41","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.cpet.2018.02.006","volume":"13","author":"T-A Moo","year":"2018","unstructured":"Moo T-A, Sanford R, Dang C, Morrow M (2018) Overview of breast cancer therapy. PET Clin 13:339\u2013354","journal-title":"PET Clin"},{"key":"191_CR42","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s41586-021-03558-4","volume":"594","author":"SM Neerven","year":"2021","unstructured":"Neerven SM, van, Groot NE, de, Nijman LE, Scicluna BP, Driel MS, van, Lecca MC, Warmerdam DO, Kakkar V, Moreno LF, Braga FAV et al (2021) Apc-mutant cells act as supercompetitors in intestinal tumour initiation. Nature 594:436\u2013441","journal-title":"Nature"},{"key":"191_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08098-6","volume":"10","author":"D Nichol","year":"2019","unstructured":"Nichol D, Rutter J, Bryant C, Hujer AM, Lek S, Adams MD, Jeavons P, Anderson ARA, Bonomo RA, Scott JG (2019) Antibiotic collateral sensitivity is contingent on the repeatability of evolution. Nat Commun 10:334","journal-title":"Nat Commun"},{"key":"191_CR44","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s42003-020-01529-5","volume":"4","author":"M Paczkowski","year":"2021","unstructured":"Paczkowski M, Kretzschmar WW, Markelc B, Liu SK, Kunz-Schughart LA, Harris AL, Partridge M, Byrne HM, Kannan P (2021) Reciprocal interactions between tumour cell populations enhance growth and reduce radiation sensitivity in prostate cancer. Commun Biol 4:6","journal-title":"Commun Biol"},{"key":"191_CR45","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/1078-0432.CCR-21-2275","volume":"28","author":"AC Palmer","year":"2022","unstructured":"Palmer AC, Izar B, Hwangbo H, Sorger PK (2022) Predictable clinical benefits without evidence of synergy in trials of combination therapies with immune-checkpoint inhibitors. Clin Cancer Res 28:368\u2013377","journal-title":"Clin Cancer Res"},{"key":"191_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semcancer.2019.07.008","volume":"63","author":"CJ Pelham","year":"2020","unstructured":"Pelham CJ, Nagane M, Madan E (2020) Cell competition in tumor evolution and heterogeneity: Merging past and present. Semin Cancer Biol 63:11\u201318","journal-title":"Semin Cancer Biol"},{"key":"191_CR47","doi-asserted-by":"publisher","unstructured":"Robertson-Tessi M, Brown JS, Poole MI, Johnson M, Marusyk A, Gallaher JA, Luddy KA, Whelan CJ, West J, Strobl M et al (2023) Feasibility of an evolutionary tumor board for generating novel personalized therapeutic strategies. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2023.01.18.23284628","DOI":"10.1101\/2023.01.18.23284628"},{"key":"191_CR48","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev-cancerbio-061421-020411","volume":"7","author":"EV Schmidt","year":"2023","unstructured":"Schmidt EV, Sun LZ, Palmer AC, Chen C (2023) Rationales for combining therapies to treat cancer: independent action, response correlation, and collateral sensitivity versus synergy. Annu Rev Cancer Biol 7:247\u2013263","journal-title":"Annu Rev Cancer Biol"},{"key":"191_CR49","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/jamaoncol.2018.3395","volume":"5","author":"K Stankov\u00e1","year":"2018","unstructured":"Stankov\u00e1 K, Brown JS, Dalton WS, Gatenby RA (2018) Optimizing cancer treatment using game theory: a review. JAMA Oncol 5:96\u2013103","journal-title":"JAMA Oncol"},{"key":"191_CR51","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.annonc.2023.08.008","volume":"34","author":"MAR Strobl","year":"2023","unstructured":"Strobl MAR, Gallaher J, Robertson-Tessi M, West J, Anderson ARA (2023) Treatment of evolving cancers will require dynamic decision support. Ann Oncol 34:867\u2013884","journal-title":"Ann Oncol"},{"key":"191_CR52","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/nrurol.2014.303","volume":"11","author":"C Thoma","year":"2014","unstructured":"Thoma C (2014) Copper unlocks therapeutic potential of disulfiram. Nat Rev Urol 11:664\u2013664","journal-title":"Nat Rev Urol"},{"key":"191_CR53","first-page":"2920","volume":"12","author":"M Tufail","year":"2022","unstructured":"Tufail M, Cui J, Wu C (2022) Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches. Am J cancer Res 12:2920\u20132949","journal-title":"Am J cancer Res"},{"key":"191_CR50","unstructured":"Wild CP, Weiderpass E, Stewart BW (eds) (2003) World cancer report. IARC Press, Lyon"},{"key":"191_CR54","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.3390\/cancers13215262","volume":"13","author":"J Wang","year":"2021","unstructured":"Wang J, Zhang Y, Liu X, Liu H (2021) Optimizing adaptive therapy based on the reachability to tumor resistant subpopulation. Cancers 13:5262","journal-title":"Cancers"},{"key":"191_CR55","doi-asserted-by":"publisher","first-page":"11046","DOI":"10.3390\/ijms231911046","volume":"23","author":"Y Wang","year":"2022","unstructured":"Wang Y, Minden A (2022) Current molecular combination therapies used for the treatment of breast cancer. Int J Mol Sci 23:11046","journal-title":"Int J Mol Sci"},{"key":"191_CR66","doi-asserted-by":"crossref","unstructured":"Weber K, Bartsch U, Stocking C, Fehse B (2008) A multicolor panel of novel lentiviral \u2018gene ontology\u2019 (LeGO) vectorsfor functional gene analysis. Mol Ther 16:698\u2013706","DOI":"10.1038\/mt.2008.6"},{"key":"191_CR56","doi-asserted-by":"publisher","first-page":"e234149","DOI":"10.1001\/jamanetworkopen.2023.4149","volume":"6","author":"K Werlenius","year":"2023","unstructured":"Werlenius K, Kinhult S, Solheim TS, Magelssen H, L\u00f6fgren D, Mudaisi M, Hylin S, Bartek J, Strand\u00e9us M, Lindskog M et al (2023) Effect of disulfiram and copper plus chemotherapy vs chemotherapy alone on survival in patients with recurrent glioblastoma. JAMA Netw Open 6:e234149","journal-title":"JAMA Netw Open"},{"key":"191_CR57","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s13235-021-00397-w","volume":"12","author":"B W\u00f6lfl","year":"2022","unstructured":"W\u00f6lfl B, Rietmole H, te, Salvioli M, Kaznatcheev A, Thuijsman F, Brown JS, Burgering B, Sta\u0148kov\u00e1 K (2022) The contribution of evolutionary game theory to understanding and treating. Cancer Dyn Games Appl 12:313\u2013342","journal-title":"Cancer Dyn Games Appl"},{"key":"191_CR58","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","volume":"339","author":"AJJ Wood","year":"1998","unstructured":"Wood AJJ, Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609\u20131618","journal-title":"N Engl J Med"},{"key":"191_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24789-z","volume":"12","author":"DJ Wooten","year":"2021","unstructured":"Wooten DJ, Meyer CT, Lubbock ALR, Quaranta V, Lopez CF (2021) MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery. Nat Commun 12:4607","journal-title":"Nat Commun"},{"key":"191_CR60","doi-asserted-by":"publisher","first-page":"20140028","DOI":"10.1098\/rsfs.2014.0028","volume":"4","author":"A Wu","year":"2014","unstructured":"Wu A, Liao D, Tlsty TD, Sturm JC, Austin RH (2014a) Game theory in the death galaxy: interaction of cancer and stromal cells in tumour microenvironment. Interface Focus 4:20140028","journal-title":"Interface Focus"},{"key":"191_CR61","doi-asserted-by":"publisher","first-page":"20140028","DOI":"10.1098\/rsfs.2014.0028","volume":"4","author":"A Wu","year":"2014","unstructured":"Wu A, Liao D, Tlsty TD, Sturm JC, Austin RH (2014b) Game theory in the death galaxy: interaction of cancer and stromal cells in tumour microenvironment. Interface Focus 4:20140028","journal-title":"Interface Focus"},{"key":"191_CR62","doi-asserted-by":"publisher","first-page":"972146","DOI":"10.3389\/fmolb.2022.972146","volume":"9","author":"EY Yang","year":"2022","unstructured":"Yang EY, Howard GR, Brock A, Yankeelov TE, Lorenzo G (2022) Mathematical characterization of population dynamics in breast cancer cells treated with doxorubicin. Front Mol Biosci 9:972146","journal-title":"Front Mol Biosci"},{"key":"191_CR63","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1158\/0008-5472.CAN-09-3752","volume":"70","author":"H Zhang","year":"2010","unstructured":"Zhang H, Chen D, Ringler J, Chen W, Cui QC, Ethier SP, Dou QP, Wu G (2010) Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Res 70:3996\u20134004","journal-title":"Cancer Res"},{"key":"191_CR64","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1039\/C7SC04853J","volume":"9","author":"P Zhao","year":"2018","unstructured":"Zhao P, Wang Y, Kang X, Wu A, Yin W, Tang Y, Wang J, Zhang M, Duan Y, Huang Y (2018) Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy. Chem Sci 9:2674\u20132689","journal-title":"Chem Sci"},{"key":"191_CR65","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T et al (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 6:201","journal-title":"Signal Transduct Target Ther"}],"container-title":["Molecular Systems Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44320-026-00191-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44320-026-00191-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44320-026-00191-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:33:03Z","timestamp":1782973983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44320-026-00191-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":66,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,2]]}},"alternative-id":["191"],"URL":"https:\/\/doi.org\/10.1038\/s44320-026-00191-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.09.03.611032","asserted-by":"object"}]},"ISSN":["1744-4292"],"issn-type":[{"value":"1744-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}